CASE REPORT article
Front. Oncol.
Sec. Gynecological Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1625521
This article is part of the Research TopicAdvances in Diagnosis and Treatment of Endometrial CancerView all 7 articles
Case Report: Trastuzumab Deruxtecan Plus Toripalimab in ERBB2-Amplified Cervical Mucosal Melanoma
Provisionally accepted
- Department of Oncology, Weihai Central Hospital, Weihai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Cervical mucosal melanoma is a rare, aggressive malignancy with poor prognosis due to delayed diagnosis and limited treatment efficacy. Current therapies, including immune checkpoint inhibitors (e.g., anti-PD-1 agents), chemotherapy, and targeted therapies, yield suboptimal response rates (<30%) and frequent resistance.Here, we report the first case of HER2-positive cervical mucosal melanoma successfully treated with T-DXd combined with Toripalimab. This combination induced significant tumor shrinkage (partial response) and demonstrated safety, highlighting the potential of ADC-based cross-tumor therapies and immune-targeted synergy. These findings support further clinical trials to validate this strategy in mucosal melanoma, addressing unmet needs in this refractory subtype.
Keywords: Cervical mucosal melanoma, Trastuzumab deruxtecan (T-DXd), Genomic profiling, Toripalimab, Her2-positive tumors
Received: 09 May 2025; Accepted: 14 Aug 2025.
Copyright: © 2025 Wang, Wang and Sui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chao Sui, Department of Oncology, Weihai Central Hospital, Weihai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.